MannKind Corp (NASDAQ:MNKD)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes and cancer.

Recs

0
Player Avatar OttawaGuy (< 20) Submitted: 8/12/2013 11:00:37 PM : Outperform Start Price: $7.03 MNKD Score: -5.89

Did a little math and it looks like $12 per million served.
P/E 18
Contribution Margin 25% or $500 per client
Share Count 550M
US Diabetic Pop. (T1 & T2) 30M
Euro Diabetic Pop. (T1 & T2) 30M
ROW (T1 & T2) 220M
World Wide Market Share 7% = 19.6M

$500 * 19.6M * 18 / 550M
= $320 pps

Featured Broker Partners


Advertisement